§.01The study, in one paragraph.
Researchers from King Saud bin Abdulaziz University and collaborators systematically searched PubMed, Scopus, and Web of Science for randomized controlled trials of ashwagandha (Withania somnifera) extracts in adults with mental health outcomes. Twenty-two studies met the eligibility criteria. They performed standard meta-analysis plus dose-response (both linear and non-linear) and subgroup analyses. Outcomes were reported as standardized mean differences (SMDs). The protocol was pre-registered with PROSPERO (CRD420251073134), which is a credibility marker — they committed to the analysis plan before running it.
§.02What the numbers actually show.
The pooled SMDs reported were unusually large for psych endpoints:
- Stress: SMD = -5.88 (95% CI: -8.15 to -3.60)
- Depression: SMD = -5.68 (95% CI: -8.43 to -2.94)
- Anxiety: SMD = -6.87 (95% CI: -8.77 to -4.97)
For context, a "moderate" effect in psychology meta-analyses is usually SMD around -0.5 to -0.8. SMDs above -2 are rare and often indicate measurement units that don't normalize well across trials, large between-study heterogeneity, or unstandardized outcome scales. The confidence intervals being entirely below zero is meaningful (the effect is statistically real, not chance). The size of the SMD point estimate is the part to interpret with caution.
The dose-response analysis was the more useful finding: there was a significant linear association between ashwagandha dose and stress reduction (coefficient = 0.005, p = 0.031) plus a non-linear component (p = 0.005). In plain terms — higher doses of ashwagandha (within the studied range, usually 300-600 mg/day) produced larger reductions in stress, with diminishing returns at the top of the curve.
§.03What it means if you are considering ashwagandha.
The headline reading: ashwagandha consistently outperformed placebo across 22 trials for stress, anxiety, and depression. That is robust evidence the supplement does something measurable for mental health endpoints in adults. The dose-response finding strengthens the case — there is a relationship between how much you take and how much benefit you get.
The honest reading: how much it does in absolute terms is harder to nail down. Different trials used different ashwagandha extracts (KSM-66 is the most-tested), different doses (most fall in 300-600 mg/day), different scales (PSS, HADS, DASS, STAI, etc.), and different durations (4-12 weeks). The pooled SMDs are a directional signal, not a precise dose calculator.
For an adult deciding whether to try ashwagandha for stress: yes, the body of evidence supports an effect. Pick a standardized extract (KSM-66 or Sensoril), use 300-600 mg/day with food, give it 4-8 weeks to evaluate. The new meta-analysis does not change the practical protocol.
§.04Limitations the authors flagged.
- Heterogeneity: the 22 studies used different extracts, doses, durations, and outcome scales. This drives the unusually wide confidence intervals.
- Risk of bias: the authors note many included trials were small (n < 100) and short (< 12 weeks). Long-term effects and safety remain less characterized.
- Industry funding: a non-trivial portion of ashwagandha RCTs are funded by extract manufacturers (KSM-66 in particular). The pooled estimate may be inflated by publication bias and selective reporting.
- Effect size interpretation: SMDs of this magnitude warrant a careful look at the raw data of each contributing trial. The authors conclude the evidence is "promising" but not yet ready to translate into "clinical recommendations."
§.05Where it fits in the broader evidence.
This meta-analysis is consistent with the prior ones (Pratte 2014, Salve 2019, Lopresti 2019) — all converged on the conclusion that ashwagandha reduces cortisol and improves stress/anxiety markers vs placebo. What this 2026 update adds is the dose-response analysis (the prior meta-analyses did not test that explicitly) and the larger pool of trials (22 vs ~5-8 in earlier syntheses).
For the supplement category, this is meaningful. Ashwagandha is one of the few botanicals with a real meta-analytic case. Most "adaptogens" do not have this level of evidence. The next question — which the authors call out — is comparative effectiveness vs SSRIs or CBT for mild-to-moderate anxiety. That trial has not been run.
§.99The bottom line.
A new 22-RCT meta-analysis confirms what the prior evidence already suggested: ashwagandha consistently reduces stress, anxiety, and depression markers vs placebo in adult RCTs, with a dose-response signal. The effect sizes reported are unusually large (SMD > -5) and probably reflect measurement-scale heterogeneity more than the absolute magnitude of clinical benefit — but the direction and statistical significance are solid. If you were already on the fence about ashwagandha for daily stress, this meta-analysis is more reason to try a standardized 300-600 mg extract for 8 weeks. If you are managing diagnosed anxiety or depression, this is not a substitute for talking to your prescriber.
Ashwagandha KSM-66, 60 capsules — at the apothecary.
§.RXThe study.
Alsanie SA, Alhodieb FS, Askarpour M — Complementary therapies in medicine, 2026 May · DOI: 10.1016/j.ctim.2026.103325
Reviewed by Dr. Marthe Janssen, PharmD on May 20, 2026. We summarize peer-reviewed research without making medical claims.
Disclaimer: this article is educational only and not medical advice. Statements about supplements have not been evaluated by the FDA. Always discuss new supplements with your prescriber.